Treatment Regimens for hetIL-15


Interleukin-15 (IL-15) is a cytokine important for both innate and adaptive immune systems.  IL-15 has potential for use in vaccines, cancer therapy, infectious disease, autoimmune disease, and as a vaccine adjuvant.  

NCI inventors  previously disclosed optimized sequences of heterodimeric IL-15 (hetIL-15), the IL-15 and IL-15 receptor alpha (IL-15Ra) heterodimer.  Recently, specific methods, drug schedules and dosage of hetIL-15 have been identified, able to induce entry of lymphocytes into tumors and germinal centers which are classically difficult for drug entry.  The regimens described have reduced toxicity and increased entry into germinal centers for HIV infection. 

The NCI researchers have also studied a combination of hetIL-15 with a therapeutic HIV vaccine incorporating conserved elements of Gag.  This combination effectively induces an immune response and maximizes the entry of immune cells into viral sanctuary sites such as germinal centers.  This combination has potential for the treatment of HIV by effectively eliminating infected cells.    



Potential Commercial Applications: Competitive Advantages:

• Therapeutic regimens for the treatment of HIV or cancer
• Combination therapy for the treatment of HIV 

 

• Allows lymphocytes to enter viral sanctuary sites such as germinal centers that are not well accessed by other HIV therapies



Development Stage:
Pre-clinical (in vivo)

Related Invention(s):
E-254-2005
E-257-2009
E-141-2008
E-103-2007
E-054-2013
E-070-2015


Inventors:

George Pavlakis (NCI)  ➽ more inventions...

Barbara Felber (NCI)  ➽ more inventions...

Antonin Valentin (NCI)  ➽ more inventions...


Intellectual Property:
Application No. 62/326,223

Publications:
Pavlakis GN, et al. Heterodimeric IL-15 Induces Effector Cell Activation and Trafficking to the Germinal Centers of SIV Infected Macaques. Abstract Number OA4-1

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-126-2016
Updated: Dec 6, 2017